Gene expression profiling of Ctr9-regulated transcriptome in ERα-positive breast cancer

Hao Zeng1, Wei Xu1

  • 1Graduate Program in Cellular and Molecular Biology, McArdle Laboratory for Cancer Research, University of Wisconsin-Madison, Madison, WI 53706, USA.

Genomics Data
|March 17, 2016
PubMed

Insights

Ctr9 loss impairs estrogen receptor-positive (ERα(+)) breast cancer cell growth and survival. High Ctr9 levels correlate with poor prognosis, especially after tamoxifen treatment, suggesting Ctr9 as a potential therapeutic target.

Area of Science:

  • Molecular Biology
  • Oncology
  • Gene Expression Analysis

Background:

  • The scaffold subunit Ctr9 (RNA polymerase II associated factor complex) has diverse cellular roles and is implicated in diseases.
  • Estrogen receptor-alpha (ERα) positive breast cancer is a major health concern, with tamoxifen being a common treatment.

Purpose of the Study:

  • To investigate the molecular mechanisms underlying Ctr9's role in promoting ERα(+) breast cancer.
  • To analyze the transcriptome regulated by Ctr9 in ERα(+) breast cancer cells.

Main Methods:

  • Microarray gene expression profiling was employed to analyze the Ctr9-regulated transcriptome.
  • Experimental details and data analysis of the microarray are provided.

Main Results:

  • Loss of Ctr9 induced morphological changes, decreased proliferation, and reduced colony formation in ERα(+) breast cancer cells.
  • A positive correlation between Ctr9 and ERα protein levels was observed.
  • High Ctr9 levels are associated with poor patient survival, particularly in tamoxifen-treated ERα(+) breast cancer.

Conclusions:

  • Ctr9 plays a significant role in the progression of ERα(+) breast cancer.
  • The findings suggest Ctr9 as a potential therapeutic target for ERα(+) breast cancer, especially in tamoxifen-treated patients.
  • The study provides valuable gene expression data (GEO: GSE73388) for further research.